Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q43136750 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010713.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q43136750 | ||
| 024 | ‡a 0000-0001-7807-7751 ‡2 orcid | ||
| 024 | ‡a 23398598400 ‡2 scopus | ||
| 035 | ‡a (OCoLC)Q43136750 | ||
| 100 | 0 | ‡a Ján Rosa ‡c researcher ‡9 en | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a Ján Rosa ‡c onderzoeker ‡9 nl | |
| 670 | ‡a Author's Adrenalectomy improves arterial stiffness in primary aldosteronism | ||
| 670 | ‡a Author's Biochemical Testing After Pheochromocytoma Removal: How Early? | ||
| 670 | ‡a Author's Blood pressure changes after renal denervation at 10 European expert centers. | ||
| 670 | ‡a Author's Changes in energy metabolism in pheochromocytoma. | ||
| 670 | ‡a Author's Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. | ||
| 670 | ‡a Author's Discrepant results of adrenal venous sampling in seven patients with primary aldosteronism | ||
| 670 | ‡a Author's Hyperresponders vs. nonresponder patients after renal denervation: do they differ? | ||
| 670 | ‡a Author's Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? | ||
| 670 | ‡a Author's Left ventricle remodeling in men with moderate to severe volume-dependent hypertension | ||
| 670 | ‡a Author's Long-Term Effect of Adrenalectomy on Cardiovascular Remodeling in Patients With Pheochromocytoma | ||
| 670 | ‡a Author's Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness | ||
| 670 | ‡a Author's Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism | ||
| 670 | ‡a Author's Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. | ||
| 670 | ‡a Author's Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. | ||
| 670 | ‡a Author's Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. | ||
| 670 | ‡a Author's Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study | ||
| 670 | ‡a Author's Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. | ||
| 670 | ‡a Author's Risk Factors for Nonadherence to Antihypertensive Treatment. | ||
| 670 | ‡a Author's Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study | ||
| 670 | ‡a Author's Should All Patients with Resistant Hypertension Receive Spironolactone? | ||
| 670 | ‡a Author's The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. | ||
| 670 | ‡a Author's Vascular disturbances in primary aldosteronism: clinical evidence | ||
| 670 | ‡a wikidata authority control ‡u https://viaf.org/viaf/891154381147230292829 | ||
| 670 | ‡a wikidata authority control ‡u https://viaf.org/processed/NKC|xx0229097 | ||
| 909 | ‡a (scopus) 23398598400 ‡9 1 | ||
| 909 | ‡a (orcid) 0000000178077751 ‡9 1 | ||
| 919 | ‡a hyperrespondersvsnonresponderpatientsafterrenaldenervationdotheydiffer ‡A Hyperresponders vs. nonresponder patients after renal denervation: do they differ? ‡9 1 | ||
| 919 | ‡a combinationantihypertensivetherapyinclinicalpracticetheanalysisof1254consecutivepatientswithuncontrolledhypertension ‡A Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. ‡9 1 | ||
| 919 | ‡a changesinenergymetabolisminpheochromocytoma ‡A Changes in energy metabolism in pheochromocytoma. ‡9 1 | ||
| 919 | ‡a bloodpressurechangesafterrenaldenervationat10europeanexpertcenters ‡A Blood pressure changes after renal denervation at 10 European expert centers. ‡9 1 | ||
| 919 | ‡a biochemicaltestingafterpheochromocytomaremovalhowearly ‡A Biochemical Testing After Pheochromocytoma Removal: How Early? ‡9 1 | ||
| 919 | ‡a adrenalectomyimprovesarterialstiffnessinprimaryaldosteronism ‡A Adrenalectomy improves arterial stiffness in primary aldosteronism ‡9 1 | ||
| 919 | ‡a discrepantresultsofadrenalvenoussamplingin7patientswithprimaryaldosteronism ‡A Discrepant results of adrenal venous sampling in seven patients with primary aldosteronism ‡9 1 | ||
| 919 | ‡a vasculardisturbancesinprimaryaldosteronismclinicalevidence ‡A Vascular disturbances in primary aldosteronism: clinical evidence ‡9 1 | ||
| 919 | ‡a prevalenceofmetabolicsyndromeanditscomponentsin2maintypesofprimaryaldosteronism ‡A The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. ‡9 1 | ||
| 919 | ‡a shouldallpatientswithresistanthypertensionreceivespironolactone ‡A Should All Patients with Resistant Hypertension Receive Spironolactone? ‡9 1 | ||
| 919 | ‡a roleofaddingspironolactoneandrenaldenervationintrueresistanthypertension1yearoutcomesofrandomizedprague15study ‡A Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study ‡9 1 | ||
| 919 | ‡a riskfactorsfornonadherencetoantihypertensivetreatment ‡A Risk Factors for Nonadherence to Antihypertensive Treatment. ‡9 1 | ||
| 919 | ‡a renaldenervationincomparisonwithintensifiedpharmacotherapyintrueresistanthypertension2yearoutcomesofrandomizedprague15study ‡A Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. ‡9 1 | ||
| 919 | ‡a randomizedcomparisonofrenaldenervationversusintensifiedpharmacotherapyincludingspironolactoneintrueresistanthypertension6monthresultsfromtheprague15study ‡A Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study ‡9 1 | ||
| 919 | ‡a pulsewavevelocityinprimaryhyperparathyroidismandeffectofsurgicaltherapy ‡A Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. ‡9 1 | ||
| 919 | ‡a preciseassessmentofnoncompliancewiththeantihypertensivetherapyinpatientswithresistanthypertensionusingtoxicologicalserumanalysis ‡A Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. ‡9 1 | ||
| 919 | ‡a metaanalysisofrandomizedcontrolledtrialsofrenaldenervationintreatmentresistanthypertension ‡A Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. ‡9 1 | ||
| 919 | ‡a longtermeffectsofadrenalectomyorspironolactoneonbloodpressurecontrolandregressionofleftventriclehypertrophyinpatientswithprimaryaldosteronism ‡A Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism ‡9 1 | ||
| 919 | ‡a longtermeffectofspecifictreatmentofprimaryaldosteronismoncarotidintimamediathickness ‡A Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness ‡9 1 | ||
| 919 | ‡a longtermeffectofadrenalectomyoncardiovascularremodelinginpatientswithpheochromocytoma ‡A Long-Term Effect of Adrenalectomy on Cardiovascular Remodeling in Patients With Pheochromocytoma ‡9 1 | ||
| 919 | ‡a leftventricleremodelinginmenwithmoderatetoseverevolumedependenthypertension ‡A Left ventricle remodeling in men with moderate to severe volume-dependent hypertension ‡9 1 | ||
| 919 | ‡a importanceofthoroughinvestigationofresistanthypertensionbeforerenaldenervationshouldcompliancetotreatmentbeevaluatedsystematically ‡A Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 BNF|17113649 | ||
| 996 | ‡2 BNCHL|10000000000000000080404 | ||
| 996 | ‡2 ISNI|0000000118677093 | ||
| 996 | ‡2 LC|no2005051887 | ||
| 996 | ‡2 ISNI|0000000060320672 | ||
| 996 | ‡2 LC|ns2024000956 | ||
| 996 | ‡2 NTA|268892970 | ||
| 996 | ‡2 LC|n 79136526 | ||
| 996 | ‡2 LC|no2014147755 | ||
| 996 | ‡2 LC|no2010019959 | ||
| 996 | ‡2 SUDOC|027108449 | ||
| 996 | ‡2 NII|DA0096805X | ||
| 996 | ‡2 DNB|115200665 | ||
| 996 | ‡2 SUDOC|190762306 | ||
| 996 | ‡2 CAOONL|ncf10350383 | ||
| 996 | ‡2 DNB|1158211686 | ||
| 996 | ‡2 BNE|XX5023790 | ||
| 996 | ‡2 SUDOC|087492199 | ||
| 996 | ‡2 BNC|981058524459806706 | ||
| 996 | ‡2 BIBSYS|90218755 | ||
| 996 | ‡2 NII|DA11539124 | ||
| 996 | ‡2 LC|n 99027737 | ||
| 996 | ‡2 LC|no2006087538 | ||
| 996 | ‡2 BNE|XX943688 | ||
| 996 | ‡2 BNCHL|10000000000000000053263 | ||
| 996 | ‡2 DNB|121374025 | ||
| 996 | ‡2 ISNI|0000000078929451 | ||
| 996 | ‡2 LC|ns2019000066 | ||
| 996 | ‡2 RERO|A003759440 | ||
| 996 | ‡2 ISNI|0000000070321329 | ||
| 996 | ‡2 LC|n 80149216 | ||
| 996 | ‡2 J9U|987007417667405171 | ||
| 996 | ‡2 DNB|1115817353 | ||
| 996 | ‡2 BNC|981058612624006706 | ||
| 996 | ‡2 LC|no2011172197 | ||
| 996 | ‡2 BNE|XX1131225 | ||
| 996 | ‡2 BNC|981058525080106706 | ||
| 996 | ‡2 NII|DA04688292 | ||
| 996 | ‡2 ISNI|0000000116386751 | ||
| 996 | ‡2 BNE|XX1338068 | ||
| 996 | ‡2 LC|ns2011000277 | ||
| 996 | ‡2 BNE|XX5748339 | ||
| 996 | ‡2 LC|no2009089593 | ||
| 996 | ‡2 BNCHL|10000000000000000115460 | ||
| 996 | ‡2 BNE|XX1035283 | ||
| 996 | ‡2 ISNI|0000000108345810 | ||
| 996 | ‡2 NKC|xx0056448 | ||
| 996 | ‡2 NSK|000010698 | ||
| 996 | ‡2 ISNI|000000004722378X | ||
| 996 | ‡2 NTA|108496376 | ||
| 996 | ‡2 DNB|1056291532 | ||
| 996 | ‡2 BAV|495_38818 | ||
| 996 | ‡2 BNE|XX1110746 | ||
| 996 | ‡2 LC|no2006023197 | ||
| 996 | ‡2 ISNI|0000000395102634 | ||
| 996 | ‡2 SUDOC|264479548 | ||
| 996 | ‡2 DNB|140622128 | ||
| 996 | ‡2 ISNI|0000000069486185 | ||
| 996 | ‡2 LC|no2017123146 | ||
| 996 | ‡2 ISNI|0000000051707357 | ||
| 996 | ‡2 DNB|1027199623 | ||
| 996 | ‡2 ISNI|0000000078208291 | ||
| 996 | ‡2 RERO|A003759421 | ||
| 996 | ‡2 RERO|A003759420 | ||
| 996 | ‡2 SUDOC|027108422 | ||
| 996 | ‡2 ISNI|0000000384987713 | ||
| 996 | ‡2 SUDOC|159789737 | ||
| 996 | ‡2 LC|n 88604052 | ||
| 996 | ‡2 BNCHL|10000000000000000248539 | ||
| 996 | ‡2 SUDOC|152909435 | ||
| 996 | ‡2 DNB|1148114351 | ||
| 996 | ‡2 NDL|00454618 | ||
| 996 | ‡2 LC|no2016116682 | ||
| 996 | ‡2 NUKAT|n 2016140296 | ||
| 996 | ‡2 BNCHL|10000000000000000211763 | ||
| 996 | ‡2 NTA|069954925 | ||
| 996 | ‡2 DNB|115364420 | ||
| 996 | ‡2 NUKAT|n 2005118301 | ||
| 996 | ‡2 BNE|XX6232721 | ||
| 996 | ‡2 BAV|495_38819 | ||
| 996 | ‡2 BNE|XX5591766 | ||
| 996 | ‡2 ISNI|0000000356729450 | ||
| 996 | ‡2 PTBNP|372131 | ||
| 996 | ‡2 PTBNP|110871 | ||
| 996 | ‡2 ISNI|0000000048256532 | ||
| 996 | ‡2 NUKAT|n 2013065612 | ||
| 996 | ‡2 BNF|12233713 | ||
| 996 | ‡2 ISNI|0000000119737481 | ||
| 996 | ‡2 BNE|XX5602761 | ||
| 996 | ‡2 RERO|A017749719 | ||
| 996 | ‡2 NTA|070919550 | ||
| 996 | ‡2 ISNI|0000000020362296 | ||
| 996 | ‡2 BNF|14511115 | ||
| 996 | ‡2 BNC|981058525030306706 | ||
| 996 | ‡2 BNCHL|10000000000000000078326 | ||
| 996 | ‡2 LC|ns2011001345 | ||
| 996 | ‡2 ISNI|0000000061207719 | ||
| 996 | ‡2 LC|n 80085953 | ||
| 996 | ‡2 SUDOC|085698385 | ||
| 996 | ‡2 SUDOC|182103307 | ||
| 996 | ‡2 NUKAT|n 2009080794 | ||
| 996 | ‡2 J9U|987007268276705171 | ||
| 996 | ‡2 BNE|XX4579963 | ||
| 996 | ‡2 ISNI|0000000033750407 | ||
| 996 | ‡2 ISNI|0000000112967129 | ||
| 996 | ‡2 NKC|jo2011555983 | ||
| 996 | ‡2 BNE|XX6089901 | ||
| 996 | ‡2 BLBNB|001130953 | ||
| 996 | ‡2 DNB|1061607135 | ||
| 996 | ‡2 NUKAT|n 2020044369 | ||
| 996 | ‡2 BNC|981058529524006706 | ||
| 996 | ‡2 LC|nr 90013638 | ||
| 996 | ‡2 LC|no2003023765 | ||
| 996 | ‡2 BNE|XX1097730 | ||
| 996 | ‡2 JPG|500389799 | ||
| 996 | ‡2 LC|n 2006058431 | ||
| 996 | ‡2 DNB|1057570990 | ||
| 996 | ‡2 LC|n 82093795 | ||
| 996 | ‡2 RERO|A008865588 | ||
| 996 | ‡2 LC|no2011076674 | ||
| 996 | ‡2 SUDOC|192916351 | ||
| 996 | ‡2 LC|n 80061183 | ||
| 996 | ‡2 BNC|981058610606506706 | ||
| 996 | ‡2 NSK|000462034 | ||
| 996 | ‡2 LC|n 80067795 | ||
| 996 | ‡2 BNF|11922575 | ||
| 996 | ‡2 BNF|11922576 | ||
| 996 | ‡2 BNE|XX1221028 | ||
| 996 | ‡2 LC|nb2005000558 | ||
| 996 | ‡2 ISNI|0000000120010896 | ||
| 996 | ‡2 RERO|A011744700 | ||
| 996 | ‡2 PTBNP|205829 | ||
| 996 | ‡2 PTBNP|112173 | ||
| 996 | ‡2 ISNI|0000000045889406 | ||
| 996 | ‡2 J9U|987007302537405171 | ||
| 996 | ‡2 BNF|12635964 | ||
| 996 | ‡2 NSK|000484018 | ||
| 996 | ‡2 LC|nr 99039467 | ||
| 996 | ‡2 ISNI|0000000401279031 | ||
| 996 | ‡2 LC|ns2012001922 | ||
| 996 | ‡2 PLWABN|9810574288605606 | ||
| 996 | ‡2 BNE|XX843840 | ||
| 996 | ‡2 J9U|987007397796605171 | ||
| 996 | ‡2 NTA|122040716 | ||
| 996 | ‡2 DNB|106126954X | ||
| 996 | ‡2 NTA|06936172X | ||
| 996 | ‡2 DNB|1056349573 | ||
| 996 | ‡2 PTBNP|950957 | ||
| 996 | ‡2 ISNI|0000000059703270 | ||
| 996 | ‡2 LC|nr2002040307 | ||
| 996 | ‡2 PLWABN|9810613960205606 | ||
| 996 | ‡2 BNCHL|10000000000000000168616 | ||
| 996 | ‡2 ISNI|000000006294207X | ||
| 996 | ‡2 ISNI|000000005351636X | ||
| 996 | ‡2 LC|nr2006002835 | ||
| 996 | ‡2 ISNI|0000000426611344 | ||
| 996 | ‡2 BNF|15024506 | ||
| 996 | ‡2 SUDOC|059160055 | ||
| 996 | ‡2 DNB|1056575093 | ||
| 996 | ‡2 ISNI|0000000116066563 | ||
| 996 | ‡2 LC|no2017134712 | ||
| 996 | ‡2 SUDOC|143879820 | ||
| 996 | ‡2 BLBNB|000927878 | ||
| 996 | ‡2 NUKAT|n 99040791 | ||
| 996 | ‡2 LC|n 2020002632 | ||
| 996 | ‡2 LC|no2023128206 | ||
| 996 | ‡2 PLWABN|9812218105405606 | ||
| 996 | ‡2 LC|ns2011001093 | ||
| 996 | ‡2 BNE|XX5073962 | ||
| 996 | ‡2 LC|no2018022171 | ||
| 996 | ‡2 LC|n 89673414 | ||
| 996 | ‡2 JPG|500036258 | ||
| 996 | ‡2 NTA|323264433 | ||
| 996 | ‡2 DNB|125352498X | ||
| 996 | ‡2 ISNI|0000000079859248 | ||
| 996 | ‡2 CAOONL|ncf11276413 | ||
| 996 | ‡2 ISNI|0000000440184705 | ||
| 996 | ‡2 ISNI|0000000066592572 | ||
| 996 | ‡2 RERO|A011056968 | ||
| 996 | ‡2 LC|ns2015004053 | ||
| 996 | ‡2 ISNI|0000000358196635 | ||
| 996 | ‡2 NUKAT|n 2004092049 | ||
| 996 | ‡2 BNE|XX1751458 | ||
| 996 | ‡2 SIMACOB|207767651 | ||
| 996 | ‡2 SUDOC|281483310 | ||
| 996 | ‡2 BNE|XX1712147 | ||
| 996 | ‡2 NTA|163332037 | ||
| 996 | ‡2 ISNI|0000000021499171 | ||
| 996 | ‡2 RERO|A003759451 | ||
| 996 | ‡2 LC|ns2013003298 | ||
| 996 | ‡2 BNCHL|10000000000000000048114 | ||
| 996 | ‡2 ISNI|000000003175245X | ||
| 996 | ‡2 JPG|500020978 | ||
| 996 | ‡2 BNF|15896890 | ||
| 996 | ‡2 NTA|151044686 | ||
| 996 | ‡2 DNB|173368352 | ||
| 996 | ‡2 LC|n 83149618 | ||
| 996 | ‡2 DNB|141567384 | ||
| 996 | ‡2 BNE|XX6208162 | ||
| 996 | ‡2 J9U|987008729549405171 | ||
| 996 | ‡2 DNB|1297559339 | ||
| 996 | ‡2 BNF|14765562 | ||
| 996 | ‡2 J9U|987012124159105171 | ||
| 996 | ‡2 ICCU|TO0V056841 | ||
| 996 | ‡2 ISNI|0000000106561659 | ||
| 996 | ‡2 ISNI|000000003262904X | ||
| 996 | ‡2 NSK|000792655 | ||
| 996 | ‡2 ISNI|0000000108684687 | ||
| 996 | ‡2 DNB|1220366943 | ||
| 996 | ‡2 DNB|135062942 | ||
| 996 | ‡2 ISNI|0000000118673439 | ||
| 996 | ‡2 ISNI|0000000077151529 | ||
| 996 | ‡2 NKC|zmp20211119459 | ||
| 996 | ‡2 DNB|1057669725 | ||
| 996 | ‡2 NTA|266741010 | ||
| 996 | ‡2 BNF|13620422 | ||
| 996 | ‡2 BNF|15512427 | ||
| 996 | ‡2 LC|n 2012010667 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 | ||
| 998 | ‡a Rosa, Ján ‡2 NKC|xx0229097 ‡3 suggested ‡3 standard number |
